{"id":15360,"date":"2023-08-07T00:30:00","date_gmt":"2023-08-06T16:30:00","guid":{"rendered":"https:\/\/flcube.com\/?p=15360"},"modified":"2024-11-28T00:34:22","modified_gmt":"2024-11-27T16:34:22","slug":"guangdong-pharmaceutical-association-releases-updated-off-label-drug-list-for-2023","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=15360","title":{"rendered":"GuangDong Pharmaceutical Association Releases Updated Off-Label Drug List for 2023"},"content":{"rendered":"\n<p>The GuangDong Pharmaceutical Association has released the 2023 version of its off-label drug list, marking the 9th edition since its inception in 2015. The list serves as a reference tool rather than a recommendation guide. Contributors to this comprehensive list include Class 3A hospitals from various provinces across China, including Hebei, Shanxi, Liaoning, Heilongjiang, Shanghai, Jiangsu, Zhejiang, Anhui, Hubei, Hunan, Hainan, Chongqing, Sichuan, Shaanxi, Fujian, and Xinjiang, in addition to Guangdong.<\/p>\n\n\n\n<p><strong>Changes and New Additions to the List<\/strong><br>The updated list features 47 new drugs, while 10 products have been removed. Notable new entries include MSD\u2019s PD-1 inhibitor Keytruda (pembrolizumab), Bristol-Myers Squibb&#8217;s (BMS, <a href=\"https:\/\/www.google.com\/finance\/quote\/BMY:NYSE\">NYSE: BMY<\/a>) Opdivo (nivolumab), and AbbVie\u2019s (<a href=\"https:\/\/www.google.com\/finance\/quote\/ABBV:NYSE\">NYSE: ABBV<\/a>) Humira (adalimumab), which are among the pharmaceutical industry&#8217;s blockbuster drugs. Keytruda, in particular, is now listed for seven off-label indications.<\/p>\n\n\n\n<p><strong>Classification and Considerations for New Entries<\/strong><br>The majority of the new entries are classified as Class IIa, which indicates high-level evidence from randomized controlled studies both domestically and internationally. However, these drugs may have poor accessibility or low potency ratios. For measures that offer significant clinical benefits but come with higher costs, the list suggests considering treatments that patients may benefit from, weighing the balance between efficacy and economic implications.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The GuangDong Pharmaceutical Association has released the 2023 version of its off-label drug list, marking&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[234,429,428,853,849,18],"class_list":["post-15360","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-abbvie","tag-bms","tag-bristol-myers-squibb","tag-nyse-abbv","tag-nyse-bmy","tag-pd-1-l1"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GuangDong Pharmaceutical Association Releases Updated Off-Label Drug List for 2023 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The GuangDong Pharmaceutical Association has released the 2023 version of its off-label drug list, marking the 9th edition since its inception in 2015. The list serves as a reference tool rather than a recommendation guide. Contributors to this comprehensive list include Class 3A hospitals from various provinces across China, including Hebei, Shanxi, Liaoning, Heilongjiang, Shanghai, Jiangsu, Zhejiang, Anhui, Hubei, Hunan, Hainan, Chongqing, Sichuan, Shaanxi, Fujian, and Xinjiang, in addition to Guangdong.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=15360\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GuangDong Pharmaceutical Association Releases Updated Off-Label Drug List for 2023\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=15360\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-06T16:30:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-27T16:34:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15360#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15360\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GuangDong Pharmaceutical Association Releases Updated Off-Label Drug List for 2023\",\"datePublished\":\"2023-08-06T16:30:00+00:00\",\"dateModified\":\"2024-11-27T16:34:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15360\"},\"wordCount\":214,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AbbVie\",\"BMS\",\"Bristol-Myers Squibb\",\"NYSE: ABBV\",\"NYSE: BMY\",\"PD-1\\\/L1\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15360#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15360\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=15360\",\"name\":\"GuangDong Pharmaceutical Association Releases Updated Off-Label Drug List for 2023 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-08-06T16:30:00+00:00\",\"dateModified\":\"2024-11-27T16:34:22+00:00\",\"description\":\"The GuangDong Pharmaceutical Association has released the 2023 version of its off-label drug list, marking the 9th edition since its inception in 2015. The list serves as a reference tool rather than a recommendation guide. Contributors to this comprehensive list include Class 3A hospitals from various provinces across China, including Hebei, Shanxi, Liaoning, Heilongjiang, Shanghai, Jiangsu, Zhejiang, Anhui, Hubei, Hunan, Hainan, Chongqing, Sichuan, Shaanxi, Fujian, and Xinjiang, in addition to Guangdong.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15360#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15360\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15360#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GuangDong Pharmaceutical Association Releases Updated Off-Label Drug List for 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GuangDong Pharmaceutical Association Releases Updated Off-Label Drug List for 2023 - Insight, China&#039;s Pharmaceutical Industry","description":"The GuangDong Pharmaceutical Association has released the 2023 version of its off-label drug list, marking the 9th edition since its inception in 2015. The list serves as a reference tool rather than a recommendation guide. Contributors to this comprehensive list include Class 3A hospitals from various provinces across China, including Hebei, Shanxi, Liaoning, Heilongjiang, Shanghai, Jiangsu, Zhejiang, Anhui, Hubei, Hunan, Hainan, Chongqing, Sichuan, Shaanxi, Fujian, and Xinjiang, in addition to Guangdong.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=15360","og_locale":"en_US","og_type":"article","og_title":"GuangDong Pharmaceutical Association Releases Updated Off-Label Drug List for 2023","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=15360","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-08-06T16:30:00+00:00","article_modified_time":"2024-11-27T16:34:22+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=15360#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=15360"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GuangDong Pharmaceutical Association Releases Updated Off-Label Drug List for 2023","datePublished":"2023-08-06T16:30:00+00:00","dateModified":"2024-11-27T16:34:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=15360"},"wordCount":214,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AbbVie","BMS","Bristol-Myers Squibb","NYSE: ABBV","NYSE: BMY","PD-1\/L1"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=15360#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=15360","url":"https:\/\/flcube.com\/?p=15360","name":"GuangDong Pharmaceutical Association Releases Updated Off-Label Drug List for 2023 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-08-06T16:30:00+00:00","dateModified":"2024-11-27T16:34:22+00:00","description":"The GuangDong Pharmaceutical Association has released the 2023 version of its off-label drug list, marking the 9th edition since its inception in 2015. The list serves as a reference tool rather than a recommendation guide. Contributors to this comprehensive list include Class 3A hospitals from various provinces across China, including Hebei, Shanxi, Liaoning, Heilongjiang, Shanghai, Jiangsu, Zhejiang, Anhui, Hubei, Hunan, Hainan, Chongqing, Sichuan, Shaanxi, Fujian, and Xinjiang, in addition to Guangdong.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=15360#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=15360"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=15360#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GuangDong Pharmaceutical Association Releases Updated Off-Label Drug List for 2023"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15360"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15360\/revisions"}],"predecessor-version":[{"id":15363,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15360\/revisions\/15363"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15360"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15360"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}